摘要
目的观察复方健胰胶囊对非酒精性脂肪肝病(non-alcoholic fatty liver disease,NAFLD)患者血清相关炎性因子的影响,探讨其作用机制。方法将60例NAFLD患者分为对照组和治疗组各30例,对照组予常规治疗,治疗组在对照组基础上加用复方健胰胶囊,疗程1个月,观察两组中医证候疗效及两组治疗前后血清超敏C-反应蛋白(high sensitive C-reactive protein,hs-CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-18(interleukin-18,IL-18)的变化。结果治疗组中医证候疗效显著优于对照组(P<0.01)。治疗后对照组hs-CRP、IL-18均较治疗前显著降低(P<0.01);治疗组治疗后hs-CRP、TNF-α和IL-18均显著降低(P<0.01),且治疗组在降低hs-CRP、TNF-α和IL-18方面显著优于对照组(P<0.01)。结论复方健胰胶囊治疗NAFLD的作用机制可能与抗炎、调节炎性因子表达有关。
Objective To observe the effects of Compound Jianyi Capsule on serum levels of inflammatory cytokines in patients with non-alcoholic fatty liver disease （NAFLD） and to investigate the action mechanism of Compound Jianyi Capsule. Methods Sixty NAFLD patients were divided into control group （n = 30） and treatment group （n = 30）. Both groups received conventional treatment, and the treatment group received Compound Jianyi Capsule as an addition. The course of treatment was one month in the two groups. After treatment, the traditional Chinese medicine （TCM） syndrome outcomes and changes in serum levels of high-sensitivity C-reactive protein （hs-CRP）, tumor necrosis factor-α （TNF-α）, and interleu- kin-18 （IL-18） were evaluated. Results After treatment, the treatment group had a significantly better TCM syndrome outcome than the control group （P〈0.01）. In addition, the control group had significantly decreased hs-CRP and IL-18 levels after treatment （P〈0.01）, and the treatment group had significantly decreased hs-CRP, TNF-α, and IL-18 levels （P〈0.01）; the treatment group had significantly higher decreases in hs-CRP, TNF-α, and IL-18 levels than the control group （P〈0.01）. Conclusion The action mechanism of Compound Jianyi Capsule in treating NAFLD may be related to its anti-inflammatory and in flammatory cytokine-regulating effects.
出处
《安徽中医药大学学报》
CAS
2014年第1期24-27,共4页
Journal of Anhui University of Chinese Medicine
基金
安徽中医学院青年科学基金项目(2012qn038)
